Abstract
Cutaneous melanoma is the most common cause of death from skin disease and two -thirds of patients with tumor manifests between 35-75 years. In the Czech Republic, the incidence is around 15 new cases per 100,000 inhabitants per year.
Patients frequently come in clinical stage I or in situ. Prognosis is affected by clinical and histological factors.
The survival of patients with melanoma is significantly prolonged compared to the past due mainly early detection of disease , however, in certain parts of the patient formed metastases, which are difficult to treat and are the cause of death. Korma still used chemotherapeutic procedures, treatment options for metastatic extend inhibitors of signaling pathways and drugs that affect the immune system , such as vemurafenib , ipilimumab , nivolumab , dabrafenib , imatinib, trametinib , sorafenib , or a new cancer vaccine.
Currently, the number of clinical trials that test the efficacy of this treatment in various schemes , and examiners entirely new drugs. Immunotherapy is gradually moves to the head of the standard options in the treatment of metastatic melanoma.